BECTON DICKINSON & CO

BDX

BECTON DICKINSON & CO

BDX

Insider Sentiment (TTM):

Last Purchase:2025-08-11Last Sale:2026-06-26Shares Purchased (TTM):5,250Shares Sold (TTM):12,108

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:239,231,039Shares Outstanding:280,640,000Institutional Ownership Pct.:85.24%

Earnings Market Reaction:

Filing Date:2026-05-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Surgical & Medical Instruments & Apparatus

SYK BSX MMM IDXG MDLN RMD

BECTON DICKINSON & CO (BDX) — SEC Financial Statements & Analysis

BECTON DICKINSON & CO (BDX) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Cash And Cash Equivalents At Carrying Value	813	740	641	735	667	711	1,717	4,459	2,348	1,180	1,416	923
Restricted Cash And Investments Current	202	284	210	62	80	102	139	28	46	54	65	101
Other Short Term Investments	3	11	8	22	16	17	445	851	827	2	8	8
Accounts Receivable Net Current	2,205	2,508	2,994	2,943	3,029	2,638	3,033	2,596	2,559	2,267	2,534	2,414
Assets Current
Assets Current	8,012	9,189	9,255	8,997	8,666	8,659	10,468	12,207	10,340	8,156	8,676	8,588
Inventory Raw Materials Net Of Reserves	801	940	-	920	892	904	-	763	777	776	-	766
Inventory Net
Inventory Net	3,357	4,085	3,894	3,949	3,723	3,860	3,843	3,255	3,229	3,304	3,273	3,588
Inventory Work In Process Net Of Reserves	396	495	-	512	487	453	-	406	376	368	-	406
Inventory Finished Goods Net Of Reserves	2,161	2,650	-	2,518	2,344	2,502	-	2,087	2,076	2,160	-	2,416
Assets Of Disposal Group Including Discontinued Op…	-	-	-	-	-	-	-	-	-	-	-	271
Other Assets Current	1,432	1,560	1,508	1,285	1,150	1,331	1,292	1,018	1,330	1,349	1,380	1,282
Assets Of Disposal Group Including Discontinued Op…	0	-	-	-	-	-	-	-	-	-	-	-
Property Plant And Equipment Gross	13,552	15,237	-	14,854	14,409	14,156	-	13,922	13,925	13,899	-	13,475
Accumulated Depreciation Depletion And Amortizatio…	7,470	8,265	-	8,036	7,763	7,554	-	7,404	7,334	7,253	-	7,002
Property Plant And Equipment Net	6,082	6,972	6,997	6,818	6,646	6,602	6,821	6,518	6,591	6,647	6,557	6,474
Goodwill	25,955	26,620	26,612	26,597	26,444	26,329	26,465	24,546	24,566	24,597	24,522	24,584
Other Intangible Assets Net	450	521	523	526	530	517	549	559	558	555	552	552
Other Assets Noncurrent	2,434	3,035	3,056	2,702	2,577	2,586	2,615	2,401	2,399	2,259	2,078	2,059
Disposal Group Including Discontinued Operation As…	0	-	-	-	-	-	-	-	-	-	-	-
Assets	50,832	54,841	55,325	54,902	54,467	54,665	57,286	55,582	54,157	52,274	52,780	53,017
Liabilities And Stockhold…
Debt Current	2,573	2,623	1,560	1,810	1,604	1,318	2,170	1,192	2,016	2,016	1,141	1,856
Accounts Payable Current	-	-	1,974	-	-	-	1,896	-	-	-	1,641	-
Accrued Liabilities Current	-	-	3,103	-	-	-	3,476	-	-	-	2,604	-
Employee Related Liabilities Current	-	-	1,346	-	-	-	1,246	-	-	-	1,115	-
Liabilities Current
Liabilities Current	8,507	8,761	8,313	8,160	7,691	7,664	8,956	6,605	7,327	7,540	6,641	6,878
Accrued Income Taxes Current	-	-	329	-	-	-	168	-	-	-	139	-
Accounts Payable And Accrued Liabilities Current	5,934	6,138	-	6,350	6,087	6,347	-	5,413	5,311	5,524	-	5,021
Liabilities Of Disposal Group Including Discontinu…	0	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Noncurrent	14,706	16,916	17,621	17,531	17,666	17,440	17,940	18,131	15,995	14,094	14,738	14,926
Pension And Other Postretirement Defined Benefit P…	1,026	1,067	1,069	908	871	939	942	907	890	894	1,023	904
Other Liabilities Noncurrent	2,460	2,815	2,933	2,831	2,998	3,418	3,558	4,071	4,297	4,414	4,582	4,373
Liabilities Of Disposal Group Including Discontinu…	0	-	-	-	-	-	-	-	-	-	-	-
Preferred Stock Value	-	-	-	-	-	-	-	-	-	-	0	0
Common Stock Value	371	371	371	371	371	371	371	371	371	371	371	371
Additional Paid In Capital Common Stock	19,768	20,103	20,075	20,024	19,971	19,768	19,893	19,847	19,795	19,741	19,720	19,681
Retained Earnings Accumulated Deficit	17,391	16,704	16,622	16,426	16,150	16,141	16,139	16,015	15,802	15,540	15,535	15,691
Stockholders Equity
Stockholders Equity	24,133	25,282	25,390	25,472	25,241	25,205	25,890	25,868	25,647	25,332	25,796	25,937
Treasury Stock Value	-11,660	-10,064	-9,808	-9,561	-9,561	-9,425	-8,807	-8,807	-8,811	-8,828	-8,305	-8,321
Accumulated Other Comprehensive Income Loss Net Of…	-1,764	-1,857	-1,895	-1,813	-1,716	-1,676	-1,732	-1,579	-1,535	-1,515	-1,548	-1,507
Liabilities And Stockholders Equity	50,832	54,841	55,325	54,902	54,467	54,665	57,286	55,582	54,157	52,274	52,780	53,017
Common Stock Par Or Stated Value Per Share	1	1	1	1	1	1	1	1	1	1	1	1
Common Stock Shares Authorized	640	640	640	640	640	640	640	640	640	640	640	640
Common Stock Shares Issued	371	371	371	371	371	371	371	371	371	371	371	371
Treasury Stock Common Shares	-	-	85	-	-	-	81	-	-	-	80	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	2.50%	-4.63%	-7.84%	-4.01%	2.45%	-	-	-	-	-	-	-
2025	-0.74%	0.58%	-9.33%	1.09%	-0.06%	6.13%	2.82%	-1.11%	-0.45%	0.60%	6.52%	15.07%
2024	1.59%	2.02%	-3.00%	-4.81%	-0.46%	-3.62%	0.16%	-0.66%	3.70%	3.05%	7.45%	1.75%
2023	-	-	-	-	-	-	4.21%	-0.96%	-3.41%	0.77%	0.46%	3.64%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	0.94	1.05	1.11	1.10	1.13	1.13	1.17	1.85	1.41	1.08	1.31	1.25
Quick Ratio	0.55	0.58	0.64	0.62	0.64	0.63	0.74	1.36	0.97	0.64	0.81	0.73
Working Capital	-495.00M	428.00M	942.00M	837.00M	975.00M	995.00M	1.51B	5.60B	3.01B	616.00M	2.04B	1.71B
Leverage & Debt
Debt to Equity	0.35	0.35	0.33	0.32	0.30	0.30	0.35	0.26	0.29	0.30	0.26	0.27
Interest Coverage TTM	-	-	-	-	-	19.29	10.16	6.09	4.43	4.26	4.67	5.08
Debt Ratio	0.17	0.16	0.15	0.15	0.14	0.14	0.16	0.12	0.14	0.14	0.13	0.13
Efficiency & Turnover
Asset Turnover TTM	0.42	0.40	0.39	0.37	0.37	0.39	0.37	0.37	0.36	0.37	0.37	0.36
Days Sales Outstanding TTM	43.11	42.84	50.36	49.09	50.80	43.37	50.35	46.11	46.02	42.59	44.51	44.38
Receivables Turnover TTM	8.47	8.52	7.25	7.44	7.19	8.42	7.25	7.92	7.93	8.57	8.20	8.22
Per Share Metrics
Diluted EPS TTM	4.06	6.15	5.82	5.52	5.21	5.95	5.86	5.07	4.75	4.39	5.15	5.41
Free Cash Flow Per Share TTM	14.79	9.21	9.28	8.88	7.90	10.25	10.76	11.29	10.50	9.18	7.39	6.09
Dividend Per Share TTM	3.16	3.14	3.13	3.13	3.05	2.94	2.85	2.85	2.89	2.91	2.97	2.97
Margin Metrics
Gross Profit Margin TTM	46.91%	46.07%	45.44%	44.76%	44.28%	45.22%	45.22%	42.06%	41.25%	41.37%	42.17%	44.87%
Operating Profit Margin TTM	10.78%	12.21%	11.81%	11.36%	10.26%	11.68%	11.88%	10.71%	10.50%	10.08%	10.90%	11.82%
Net Profit Margin TTM	5.14%	8.01%	7.68%	7.70%	7.46%	8.37%	8.45%	7.43%	6.99%	6.56%	7.66%	8.19%
Growth Metrics
Net Revenue Growth (1Y)	10.38%	6.22%	8.24%	3.86%	1.82%	5.89%	4.16%	4.11%	4.82%	4.02%	2.66%	3.45%
Net Income Growth (1Y)	-24.03%	1.74%	-1.58%	7.60%	8.71%	35.03%	14.89%	-5.52%	-8.44%	-14.62%	-12.14%	-11.22%
EPS Growth (1Y)	-22.23%	3.13%	-0.86%	8.50%	9.55%	35.31%	13.51%	-6.58%	-10.09%	-16.45%	-12.53%	-11.49%
Valuation Metrics
P/E TTM	38.50	24.47	24.75	23.95	33.51	28.88	30.96	34.58	38.97	41.29	37.08	35.93
P/B	1.82	1.70	1.64	1.49	1.99	1.98	2.04	1.97	2.09	2.08	2.13	2.16
P/S TTM	1.98	1.96	1.90	1.84	2.50	2.42	2.62	2.57	2.72	2.71	2.84	2.94
Market Cap	43.82B	42.99B	41.54B	37.96B	50.19B	49.87B	52.79B	50.93B	53.70B	52.81B	55.03B	56.02B
Enterprise Value	60.08B	61.51B	59.87B	56.50B	68.78B	67.81B	71.05B	65.77B	69.32B	67.69B	69.43B	71.77B
Calculated Values
Free Cash Flow TTM	4.15B	2.63B	2.67B	2.55B	2.27B	2.97B	3.12B	3.27B	3.04B	2.66B	2.12B	1.74B
Net Debt	16.26B	18.51B	18.33B	18.54B	18.59B	17.95B	18.25B	14.84B	15.62B	14.88B	14.40B	15.76B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-26Sale

Owner: Feld, Michael

Title: EVP, Chief Revenue Officer

Shares: 75

Price/Share: $152.80

Value: $11,460.00

Shares Owned: 21,009

Relationship: Officer

Ownership: Direct

2026-06-24Sale

Owner: Garrison, Michael David

Title: EVP & Pres Med.Essntl&BioPharm

Shares: 1,100

Price/Share: $145.66

Value: $160,226.00

Shares Owned: 13,172

Relationship: Officer

Ownership: Direct

2026-06-10Sale

Owner: Garrison, Michael David

Title: EVP & Pres Med.Essntl&BioPharm

Shares: 1,100

Price/Share: $151.48

Value: $166,628.00

Shares Owned: 14,272

Relationship: Officer

Ownership: Direct

2026-06-01Sale

Owner: Polen, Thomas E Jr

Title: Chairman, CEO and President

Shares: 2,764

Price/Share: $146.35

Value: $404,511.40

Shares Owned: 110,163

Relationship: Director,Officer

Ownership: Direct

2026-05-26Sale

Owner: Feld, Michael

Title: EVP, Chief Revenue Officer

Shares: 75

Price/Share: $147.35

Value: $11,051.25

Shares Owned: 21,084

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-26	Feld, Michael	Officer	EVP, Chief Revenue Officer	Direct	Sale	75	152.80	$11,460.00	21,009	4
2026-06-24	Garrison, Michael David	Officer	EVP & Pres Med.Essntl&BioPharm	Direct	Sale	1,100	145.66	$160,226.00	13,172	4
2026-06-10	Garrison, Michael David	Officer	EVP & Pres Med.Essntl&BioPharm	Direct	Sale	1,100	151.48	$166,628.00	14,272	4
2026-06-01	Polen, Thomas E Jr	Director,Officer	Chairman, CEO and President	Direct	Sale	2,764	146.35	$404,511.40	110,163	4
2026-05-26	Feld, Michael	Officer	EVP, Chief Revenue Officer	Direct	Sale	75	147.35	$11,051.25	21,084	4
2026-04-27	Feld, Michael	Officer	EVP, Chief Revenue Officer	Direct	Sale	74	151.94	$11,243.56	21,159	4
2026-03-26	Feld, Michael	Officer	EVP, Chief Revenue Officer	Direct	Sale	75	156.83	$11,762.25	21,233	4
2026-02-26	Feld, Michael	Officer	EVP, Chief Revenue Officer	Direct	Sale	75	181.84	$13,638.00	21,308	4
2026-02-18	Scott, Bertram L	Director	-	Direct	Sale	953	182.61	$174,027.33	36,763	4
2026-01-26	Feld, Michael	Officer	EVP, CRO & Pres. Life Sciences	Direct	Sale	75	202.73	$15,204.75	16,431	4
2026-01-15	Garrison, Michael David	Officer	EVP & Pres Med.Essntl&BioPharm	Direct	Sale	1,610	207.77	$334,509.70	12,095	4
2025-12-26	Feld, Michael	Officer	EVP, CRO & Pres. Life Sciences	Direct	Sale	74	196.08	$14,509.92	16,506	4
2025-12-17	Garrison, Michael David	Officer	EVP & Pres Med.Essntl&BioPharm	Direct	Sale	629	196.03	$123,302.87	13,105	4
2025-12-01	Feld, Michael	Officer	EVP, CRO & Pres. Life Sciences	Direct	Sale	75	193.36	$14,502.00	16,580	4
2025-11-07	Scott, Bertram L	Director	-	Direct	Sale	217	176.58	$38,317.86	35,816	4
2025-10-27	Feld, Michael	Officer	EVP & President, Life Sciences	Direct	Sale	57	186.01	$10,602.57	8,245	4
2025-09-26	Feld, Michael	Officer	EVP & President, Life Sciences	Direct	Sale	58	181.03	$10,499.74	8,302	4
2025-09-10	Fraser, Claire	Director	-	Direct	Sale	917	187.50	$171,937.50	22,226	4
2025-08-22	Feld, Michael	Officer	EVP & President, Life Sciences	Direct	Sale	57	197.99	$11,285.43	8,360	4
2025-08-11	Hayes, Gregory	Director	-	Direct	Purchase	5,250	191.57	$1,005,742.50	6,046	4
2025-08-08	Fraser, Claire	Director	-	Direct	Sale	863	192.30	$165,954.90	23,143	4
2025-07-18	Garrison, Michael David	Officer	EVP & President, Medical	Direct	Sale	1,185	180.90	$214,366.50	4,887	4
2025-06-02	Shan, David	Officer	EVP and Chief ISC Officer	Direct	Sale	1,166	171.19	$199,607.54	4,575	4
2025-04-09	Garrison, Michael David	Officer	EVP & President, Medical	Direct	Sale	479	197.28	$94,497.12	4,887	4
2025-03-18	Byrd, Richard	Officer	EVP & President Interventional	Direct	Sale	459	230.00	$105,570.00	6,952	4
2025-03-12	Byrd, Richard	Officer	EVP & President Interventional	Direct	Sale	1,940	224.91	$436,325.40	7,411	4
2025-02-12	Scott, Bertram L	Director	-	Direct	Sale	700	227.99	$159,593.00	36,033	4
2025-02-10	Henderson, Jeffrey Willia…	Director	-	Direct	Purchase	1,500	233.62	$350,430.00	8,015	4
2025-01-21	Neal, Shana Carol	Officer	EVP and Chief People Officer	Direct	Sale	787	240.00	$188,880.00	15,414	4
2025-01-21	Shan, David	Officer	EVP and Chief ISC Officer	Direct	Sale	500	240.00	$120,000.00	5,741	4
2025-01-17	Garrison, Michael David	Officer	EVP & President, Medical	Direct	Sale	597	236.51	$141,196.47	5,544	4
2025-01-07	Neal, Shana Carol	Officer	EVP and Chief People Officer	Direct	Sale	788	235.00	$185,180.00	16,201	4
2024-12-19	Garrison, Michael David	Officer	EVP & President, Medical	Direct	Sale	2,838	223.33	$633,810.54	6,141	4
2024-12-09	Goette, Roland	Officer	EVP and President, EMEA	Direct	Sale	638	219.03	$139,741.14	14,217	4
2024-12-06	Neal, Shana Carol	Officer	EVP and Chief People Officer	Direct	Sale	1,000	220.49	$220,490.00	16,989	4
2024-12-05	Shan, David	Officer	EVP and Chief ISC Officer	Direct	Sale	1,500	220.25	$330,375.00	6,285	4
2024-06-10	Spoerel, Thomas J	Officer	SVP,Controller&Chief Acct Off	Direct	Sale	300	239.31	$71,793.00	1,976	4
2024-05-15	Goette, Roland	Officer	EVP and President EMEA	Direct	Sale	3,300	236.58	$780,714.00	11,308	4
2024-05-13	Goette, Roland	Officer	EVP and President EMEA	Direct	Sale	3,300	237.11	$782,463.00	14,608	4
2024-04-30	Garrison, Michael David	Officer	EVP & President Medical	Direct	Sale	1,715	232.81	$399,269.15	5,381	4
2024-03-14	Spoerel, Thomas J	Officer	SVP,Controller&Chief Acct Off	Direct	Sale	282	238.29	$67,197.78	2,276	4
2023-12-11	Garrison, Michael David	Officer	EVP & President Medical	Direct	Sale	1,239	232.46	$288,017.94	7,274	4
2023-11-28	Byrd, Richard	Officer	EVP & President Interventional	Direct	Sale	2,156	238.47	$514,141.32	4,120	4
2023-09-05	Byrd, Richard	Officer	EVP & President Interventional	Direct	Sale	459	274.48	$125,986.32	3,444	4
2023-08-28	Fraser, Claire	Director	-	Direct	Sale	848	281.66	$238,847.68	21,608	4
2023-08-11	Hickey, David	Officer	EVP & President, Life Sciences	Direct	Sale	2,974	277.85	$826,325.90	4,199	4
2023-08-08	Garrison, Michael David	Officer	EVP & President Medical	Direct	Sale	1,300	277.13	$360,269.00	5,157	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

85.24%

Inst. Shares: 239,231,039

Shares Outstanding: 280,640,000

2025-12-31

86.08%

Inst. Shares: 245,818,432

Shares Outstanding: 285,582,000

2025-09-30

80.94%

Inst. Shares: 232,832,781

Shares Outstanding: 287,648,000

2025-06-30

78.23%

Inst. Shares: 224,663,741

Shares Outstanding: 287,170,000

2025-03-31

77.76%

Inst. Shares: 223,394,058

Shares Outstanding: 287,293,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	239,231,039	280,640,000	85.24%
2025-12-31	245,818,432	285,582,000	86.08%
2025-09-30	232,832,781	287,648,000	80.94%
2025-06-30	224,663,741	287,170,000	78.23%
2025-03-31	223,394,058	287,293,000	77.76%
2024-12-31	228,148,146	289,505,000	78.81%
2024-09-30	221,603,728	289,763,000	76.48%
2024-06-30	227,070,018	289,562,000	78.42%
2024-03-31	213,707,422	289,518,000	73.81%
2023-12-31	220,546,880	290,113,000	76.02%
2023-09-30	220,804,107	286,282,000	77.13%
2023-06-30	216,290,421	286,317,000	75.54%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

BECTON DICKINSON & CO (BDX) — SEC Financial Statements & Analysis

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.